Novartis Ag

Novartis Pharma Gmbh

Rolf Baenteli

Gebhard Thoma

Rudolf Duthaler

Gerhard Zenke

Nigel Graham Cooke

Klaus Hinterding

Anette Von Matt

Maurice Van Eis

Ichiro Umemura

Naoko Matsuura

Osamu Ohmori

Peter Buehlmayer

Christos Papageorgiou

Kazuhiko Nonomura

Louis Walliser

Marie Claude Bernhard

Toshiyuki Honda

Claus Ehrhardt

Wilfried Bauer

Sylvain Cottens

Josef Gottfried Meingassner

Ulrich Hommel

Ian Lewis

Markus Streiff

Jiri Kovarik

Hans-Günter Zerwes

Gabriele Weitz Schmidt

Fraser Glickman

J&ouml;rg Kallen

Fran&ccedil;ois Nuninger

Nigel Cooke

Marie Bernhard

There are provided compounds of formula I wherein X, R, R, R, R, R, R, R, Rand Rare as indicated in claim 1 , useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

2,4-diaminopyrimidine derivatives

Disclosed are pyrimidine derivatives of formula wherein R, R, Rto R, and Z have a signification as indicated in claim, which have interesting pharmaceutical properties.

2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors

There are provided compounds of formula I wherein X, R, R, R, R, R, R, R, Rand Rare as indicated in claim, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Disclosed are pyrimidine derivatives of formula wherein R, R, Rto R, and Z have a signification as indicated in claimwhich have interesting pharmaceutical properties.

2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors

Disclosed are ergoline derivatives, Formula (I), wherein either each of Rand R, independently, is H; optionally Rand/or R-substituted-phenyl or -phenyl-Calkyl; optionally Rand/or R-substituted-heteroaryl or -heteroaryl-Calkyl; optionally Rand/or R-substituted heteroaryl N-oxide; optionally R-substituted C-Calkyl; optionally R-substituted C-Calkenyl, optionally R-substituted C-Calkynyl; optionally R-substituted C-Ccycloalkyl, or optionally R-substituted C-Ccycloalkenyl; or Rand Rform together with the nitrogen atom to which they are attached an optionally R-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; Ris H; OR; CHRR; (CH)NRR; CH&#x2014;CH&#x2014;OR; CH&#x2014;CO&#x2014;NRR; or CO&#x2014;CHRR; Ris F; Cl; Br; I; OR; NRRor has one of the significances given for R; and Rhas one of the significances given for R, in free form or in salt form for preventing or treating disorders or diseases mediated by interactions between chemokine receptors and their ligands. 

Ergoline derivatives

Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.

Melvinolin derivatives

Growing community of inventors

Basel, Switzerland

Rolf Baenteli